





# PHARMACEUTICAL 2017

## LIXTE BIOTECHNOLOGY HOLDINGS INC. Rank 307 of 313

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 234% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 1,665% points.

The company's Economic Capital Ratio, given in the ranking table, is -2,586%, being 2,169% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	433
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	219
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0.18
Property and Equipment	0
Research and Development	1,301
Revenues	0
Selling, General and Administrative Expense	834

Output Variable	Value in 1000 USD
Assets	433
Liabilities	219
Expenses	2,135
Stockholders Equity	215
Net Income	-2,135
Comprehensive Net Income	-2,135
Economic Capital Ratio	-2,586%

